Thioflavin T kinetics

Thioflavin T (ThT) is a small benzothiazole dye that fluoresces weakly in free solution and brightly once it binds the cross-beta structure shared by amyloid fibrils. Excite it near 440 nm, read emission near 480 nm, and the signal tracks how much fibril is present. Because the dye reports on structure rather than on a specific sequence, the same assay works for tau, alpha-synuclein, amyloid-beta and many other aggregating proteins.

Read over time in a plate reader, ThT traces a sigmoidal curve with three parts: a lag phase while nuclei form, a growth phase as fibrils elongate, and a plateau once free monomer is spent. Almost everything useful in the assay comes from knowing which part of that curve moved.

Reading the curve

The lag phase reflects how long it takes to make the first competent nuclei. Anything that removes monomer from the reaction, stabilizes it in a non-aggregating state, or interferes with nucleation tends to lengthen it. Seeding with preformed fibrils shortens or abolishes it, which is the basis of seeded aggregation assays.

The growth phase reflects elongation at fibril ends, and later, in many systems, secondary nucleation on fibril surfaces. Something that caps ends or blocks the fibril surface lowers the slope without necessarily changing when growth starts.

The plateau reflects how much fibril mass the reaction reached, though only loosely. ThT binding is not perfectly proportional to mass across polymorphs, so treat the plateau as a comparison between wells in the same experiment rather than as a quantity.

What it tells you about an antibody

For antibody work, the shape of the change is the first clue to mechanism. A binder that holds monomer tends to lengthen the lag phase. A binder that caps growing ends or coats the fibril surface tends to flatten the growth phase. A binder that does neither, but that shifts the plateau, is often doing something to ThT binding rather than to aggregation, which is worth checking before it gets written up as inhibition.

None of this is a mechanism on its own. ThT gives you a hypothesis and a rank order. Confirming it usually means orthogonal measurements: sedimentation or filtration to separate soluble from insoluble material, electron microscopy for morphology, and a seeding assay in cells to ask whether the material that formed is biologically active.

Controls that decide whether the number means anything

• A dye-only control. ThT alone, with the same buffer and the same plate, sets the baseline and catches buffer components that fluoresce.
• An antibody-only control. Some antibodies and many small molecules are fluorescent or quench ThT. Without this well, quenching reads as inhibition.
• A ThT competition check. Compounds that bind the same grooves displace the dye. If the endpoint drops but the material still sediments as fibril, the compound is competing with ThT, not preventing aggregation.
• Replicates across the plate, not down one column. Aggregation kinetics are notoriously variable well to well, and plate position carries evaporation and temperature gradients with it.
• A defined seed or inducer. Tau, for example, does not aggregate readily on its own at physiological concentrations and is usually induced with a polyanion such as heparin, or seeded with preformed fibrils. Which one you choose changes the polymorph you produce, so it belongs in the method, not in a footnote.

Pitfalls we see most often

The most common is treating the lag time from a single well as a measurement. Nucleation is a stochastic process, so lag times scatter, and the spread itself is data. Run enough replicates to report a distribution rather than a point.

The second is quiet drift in the assay setup. Shaking, beads, well volume, plate material and even the seal change the balance between primary nucleation, fragmentation and surface effects. Two labs running the same protein with different shaking regimes can get curves that look like different mechanisms.

The third is reading endpoint only. A single time point cannot distinguish a delayed reaction from a suppressed one, and those have different consequences for a drug.

How we run it

We run ThT kinetics in plate format with the controls above, report the curve rather than a single number, and pair it with a cell-based seeding assay when the question is whether a molecule changes biologically active aggregation rather than in vitro fibril formation.